Gusto Global

Gusto Global is a biotechnology company that develops proprietary microbiome-based platforms for disease detection and therapeutic intervention. The company built the Tapestry platform, which uses advanced bioinformatics, computational modeling, and predictive analytics to analyze microbial cell-free DNA (mcfDNA) signatures in blood and other samples. By identifying specific microbial signatures associated with inflammation, infection, and oncology, Gusto Global aims to enable earlier and more precise diagnostics. Its technology differentiates itself by leveraging the sensitivity of microorganisms as biosensors, allowing the company to detect pathological changes before they become symptomatic or are identifiable through traditional human biomarkers.

These capabilities are critical for patients suffering from immune-mediated conditions and cancer, where traditional treatments often focus on symptom management rather than root causes. Gusto Global’s research into rationally designed bacterial consortia seeks to restore intestinal homeostasis and improve long-term patient outcomes. The company collaborates with leading organizations such as the Crohn’s & Colitis Foundation, utilizing platforms like IBD Plexus to validate its prognostic and therapeutic technologies. By integrating these microbial insights into clinical applications, Gusto Global aims to advance precision medicine, offering more effective, personalized treatment pathways for chronic and life-threatening diseases.